A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.

The 5-year survival rate for women with metastatic breast cancer is only 25-30%; thus, the need to improve treatment is apparent. Overexpression of insulin-like growth factor-I receptor (IGF-IR) correlates with poor prognosis and local recurrence. In this study, we addressed whether functional impairment of IGF-IR affects adhesion, invasion, and metastasis of breast cancer. Impairment of IGF-IR function was achieved by transfecting a dominant negative form of the receptor, termed 486stop, into MDA-MB-435 metastatic breast cancer cells. The protein product of 486stop is secreted extracellularly, resulting in a bystander effect. Cellular adhesion to laminin and collagen was inhibited 94 and 88%, respectively. Furthermore, 486stop inhibited insulin-like growth factor-I-stimulated invasion through collagen IV by 75%. The dominant negative receptor was secreted, as evidenced by the observation that MDA-MB-435 and MDA-MB-231 cells were prevented from binding to laminin by 90% when treated with conditioned medium (CM) from 486stop-transfected cells. CM also inhibited the invasion of MDA-MB-231 cells across collagen IV by 80%. Finally, CM made MDA-MB-231 cells 30% more sensitive to Taxol-induced cell death. Growth in soft agar was suppressed by 486stop, but growth in monolayer was unaffected. When injected into the mammary fat pad, 486stop did not significantly suppress growth of the primary tumor, but metastasis to the lungs, livers, lymph nodes, and lymph vessels was significantly decreased compared to the vector control. In conclusion, inhibition of IGF-IR resulted in suppression of adhesion, invasion, and metastasis, providing a mechanistic rationale for targeting IGF-IR in the treatment of metastatic breast cancer.

[1]  J. Cullen,et al.  Woodchuck p-glycoprotein found in virus-induced hepatocellular carcinomas binds anticancer drugs , 1996 .

[2]  A. Ferber,et al.  A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. , 1996, Cancer research.

[3]  Y. Kurokawa.  Experiments on lymph node metastasis by intralymphatic inoculation of rat ascites tumor cells, with special reference to lodgement, passage, and growth of tumor cells in lymph nodes. , 1970, Gan.

[4]  C. Osborne,et al.  Regulation of breast cancer growth by insulin-like growth factors , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  R. Bell,et al.  Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. , 1992, Journal of the National Cancer Institute.

[6]  Philip Smith,et al.  WHAT IS THE BIOLOGY OF INVASION AND METASTASIS IN BLADDER CANCER? , 1995, International journal of urology : official journal of the Japanese Urological Association.

[7]  R. Dickson,et al.  Induction of ductal morphogenesis and lobular hyperplasia by amphiregulin in the mouse mammary gland. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[8]  M E Doerr,et al.  The Roles of Integrins and Extracellular Matrix Proteins in the Insulin-like Growth Factor I-stimulated Chemotaxis of Human Breast Cancer Cells (*) , 1996, The Journal of Biological Chemistry.

[9]  J. French,et al.  Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. , 1997, Cancer research.

[10]  F. Grigorescu,et al.  Involvement of phosphoinositide 3‐kinase in insulin‐ or IGF‐1‐induced membrane ruffling. , 1994, The EMBO journal.

[11]  C. Redmond,et al.  Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. , 1990, Journal of the National Cancer Institute.

[12]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[13]  M. Johnson,et al.  Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. , 1990, The Journal of biological chemistry.

[14]  E. Carpenter.  Introductory text , 1967, Money and Government.

[15]  J. Price,et al.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. , 1990, Cancer research.

[16]  G. Murphy,et al.  Management and survival of female breast cancer: Results of a national survey by the American college of surgeons , 1980, Cancer.

[17]  W. Glasgow,et al.  Regulation of the adhesion of a human breast carcinoma cell line to type IV collagen and vitronectin: roles for lipoxygenase and protein kinase C. , 1996, Cancer research.

[18]  D. Coppola,et al.  Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. , 1994, Cancer research.

[19]  J. Ilan,et al.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[21]  R. Baserga,et al.  Mutant IGF-I receptors as dominant negatives for growth and transformation. , 1995, Biochemical and biophysical research communications.

[22]  P. Petrusz,et al.  Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Railo,et al.  The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. , 1994, European journal of cancer.

[24]  D. Hill,et al.  Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II) , 1995, British Journal of Cancer.

[25]  Eva L Feldman,et al.  Insulin-like Growth Factors as Regulators of Cell Motility Signaling Mechanisms , 1997, Trends in Endocrinology & Metabolism.

[26]  M. Miura,et al.  Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells. , 1995, Cancer research.

[27]  S. Asa,et al.  Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Devlin,et al.  Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. , 1989, Cancer research.

[29]  R. Baserga,et al.  Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. , 1995, Cancer research.

[30]  WR Roche,et al.  Basic Pathology , 1994 .

[31]  P. Glazer,et al.  Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. , 1997, Cancer research.

[32]  J. Bonneterre,et al.  Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. , 1993, European journal of cancer.

[33]  E. Scholar,et al.  Inhibition of invasion of murine mammary carcinoma cells by the tyrosine kinase inhibitor genistein. , 1994, Cancer letters.

[34]  M. Oshimura,et al.  Growth and transformation suppressor genes for BHK syrian hamster cells on human chromosomes 1 and 11 , 1992, Molecular carcinogenesis.

[35]  M. Rubini,et al.  The IGF-I receptor in cell growth, transformation and apoptosis. , 1997, Biochimica et biophysica acta.

[36]  H. Huynh,et al.  Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. , 1994, Biochemical and biophysical research communications.